‘We exist to improve patient care and quality of life through imagination, intuition and innovation’
‘Transforming lives through design intelligence’
MIMICS-2 3-year data released
Professor Thomas Zeller PI of the MIMICS-2 IDE study has announced that the freedom from CDTLR at 3 years for the BioMimics 3D stent was 81%, which is comparable to the outcomes for DCB, DES and Supera, despite treating more challenging lesions and without the need for lesion preparation.
The Latest from Veryan
News, updates and press releases
BioMimics 3D® Vascular Stent System granted Good Design Award 2022
TOKYO, JAPAN – 07 OCTOBER 2022 – Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”, subsidiary of Otsuka Holdings Co., Ltd.) is pleased to announce that the BioMimics 3D Vascular Stent System has been granted a Good Design Award 2022 from the Japan Institute of Design Promotion.
MIMICS-3D EU 3-year results
Veryan Medical has confirmed the release at ISET 22 of the MIMICS-3D EU 3-year results by the study PI Michael Lichtenberg MD. MIMICS-3D EU is a prospective, multicentre, observational registry to evaluate the BioMimics 3D Vascular Stent System. The study evaluated safety, effectiveness and device performance within a real-world clinical population of 507 patients enrolled in 23 pan-European sites.